With the development and application of immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1, the prognoses for some HCC patients have significantly improved (Kalathil et al., 2016; Mahn et al., 2020). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.